While Indian pharma exports were regulated years ago, the time has come to start a new era for anti-counterfeiting domestic regulation. In a candid conversation, Nakul Pasricha, President, Authentication Solutions Providers Associations (ASPA), reveals more to Akanki Sharma
How often does the Indian pharma industry face the problem of falsified and sub-standard medicines?
According to a study by the International Institute of Research Against Counterfeit Medicines (IRACM), globally, counterfeiting has been measured as about $200 billion problem in terms of statistics. According to research from WHO study, an estimated one in 10 medical products circulating in low- and middle-income countries is either substandard or falsified. Since 2013, WHO has received 1,500 reports of cases of substandard or falsified products. Of these, antimalarials and antibiotics are the most commonly reported. Prior to 2013, there was no global reporting of this information and this is likely just a small fraction of the total problem and many cases may be going unreported. A regulation by the Director General of Foreign Trade (DGFT) has been there in our country since 2011, according to which all medicines exported out of India must have barcoding.
Solutions are available if f all stakeholders – regulators, pharma companies, solution providers and consumers – come together as one and resolve to stop the spread of spurious and sub-standard medicines
What are the adverse effects of these kinds of medicines on the economy of the country?
FICCI had done a study in 2015, where it was found that the loss of tax revenue is Rs 40,000 crores (excluding pharma). Unfortunately, the study did not include pharma sector. One way to estimate is that the total Indian pharmaceutical sector valued at US$ 35 billion in 2017. The domestic market of India is $17 billion. Some independent studies have found the rate of substandard or spurious drugs to be about seven to 10 percent in India. The country's pharmaceutical exports stood at US$ 17.27 billion in FY18 and have reached US$ 19.14 billion in FY19.
This story is from the August 16-31, 2019 edition of Express Pharma.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the August 16-31, 2019 edition of Express Pharma.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Achieving Aatmanirbharta In APIs Are We On The Right Track?
As India gears up to celebrate its 75th Independence Day, self reliance in APIs remains a key goal for the pharma sector. AatmaNirbharta will be crucial for the sector as it continues to protect the country from the existing and emerging health threats
Yokogawa launches OpreX Data Model Broker
A plant data transformation platform, OpreX automatically verifies discrepancies and inconsistencies in data to improve efficiency in plant construction and operation
Understanding the nuances of generics injectables
At a webinar, explaining the West Pharma's AccelTRA Components Program, industry experts explained why the use of glass vials and stoppers as primary container closure systems (CCS) has become crucial
Trending in nutraceuticals: Science meets sustainability
Zeljko Pockaj, Vice President, Global Pharmaceutical Industry, mentions the key trends that are believed to drive innovations and formulations for nutraceuticals’ development around the globe
The growth of e-pharmacies in India
Rahul Nath Choudhury, Research fellow, ICWA, explains what motivates people in the pharma industry to invest into e-pharmacies, along with various other growth factors associated with these
Xylitol and Maltitol: Low-calorie sugar alternatives
Polyols like Xylitol and Maltitol offer important health benefits. Unlike general sugar-free sweeteners, these do not have any bitter-after taste
Single-use TC gaskets and their importance
Depending on the application, gaskets are manufactured by different types of Material of Construction (MOC) such as Silicone, EPDM, Viton (FKM), Nitrile, Neoprene, PTFE, etc.
It's important to enhance customer experience so that existing customers are more loyal
Sheshgiri Kamath, CEO and co-founder, Kapture CRM, expands on why it is important for pharma companies to enhance customer experience, and how the right CRM solution can help companies to identify, address and manage customer expectations more effectively, in an interaction with Viveka Roychowdhury
From HIV to COVID-19: The role of liposomal nanotechnology as an NDDS of choice
Arun Kedia, Managing Director,VAV Life Sciences, elaborates how NDDS have proved to be beneficial with applications across various medical therapies ranging from HIV to cancer to COVID-19 treatment
Ensuring pharma compliance with testo data loggers
Testo data loggers can be used to test the optimum conditions for specific products or surroundings